Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Sold by Vontobel Holding Ltd.

Vontobel Holding Ltd. reduced its stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 3.0% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 71,010 shares of the biopharmaceutical company’s stock after selling 2,176 shares during the period. Vontobel Holding Ltd.’s holdings in Amicus Therapeutics were worth $758,000 as of its most recent SEC filing.

Several other institutional investors have also recently modified their holdings of FOLD. Teachers Retirement System of The State of Kentucky acquired a new position in shares of Amicus Therapeutics during the 4th quarter worth approximately $1,178,000. American International Group Inc. raised its holdings in Amicus Therapeutics by 0.9% in the 4th quarter. American International Group Inc. now owns 141,249 shares of the biopharmaceutical company’s stock valued at $2,004,000 after acquiring an additional 1,298 shares during the last quarter. Vanguard Group Inc. raised its holdings in Amicus Therapeutics by 5.0% in the 4th quarter. Vanguard Group Inc. now owns 28,492,486 shares of the biopharmaceutical company’s stock valued at $404,308,000 after acquiring an additional 1,360,613 shares during the last quarter. Los Angeles Capital Management LLC raised its holdings in Amicus Therapeutics by 812.1% in the 1st quarter. Los Angeles Capital Management LLC now owns 118,360 shares of the biopharmaceutical company’s stock valued at $1,394,000 after acquiring an additional 105,384 shares during the last quarter. Finally, Diversified Trust Co raised its holdings in Amicus Therapeutics by 6.3% in the 1st quarter. Diversified Trust Co now owns 66,633 shares of the biopharmaceutical company’s stock valued at $785,000 after acquiring an additional 3,938 shares during the last quarter.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on FOLD. StockNews.com downgraded Amicus Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, October 15th. Cantor Fitzgerald restated an “overweight” rating and set a $20.00 price objective on shares of Amicus Therapeutics in a report on Friday, September 20th. Morgan Stanley dropped their price objective on Amicus Therapeutics from $19.00 to $18.00 and set an “overweight” rating for the company in a report on Friday, October 11th. JPMorgan Chase & Co. dropped their price objective on Amicus Therapeutics from $17.00 to $16.00 and set an “overweight” rating for the company in a report on Friday, August 16th. Finally, Jefferies Financial Group assumed coverage on Amicus Therapeutics in a report on Friday, September 6th. They set a “buy” rating and a $18.00 price objective for the company. Two research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat, Amicus Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $17.13.

Amicus Therapeutics Trading Down 0.6 %

Shares of NASDAQ:FOLD opened at $11.90 on Monday. The firm has a fifty day moving average of $11.17 and a two-hundred day moving average of $10.56. The firm has a market capitalization of $3.52 billion, a P/E ratio of -24.29 and a beta of 0.69. Amicus Therapeutics, Inc. has a 12-month low of $9.02 and a 12-month high of $14.57. The company has a quick ratio of 2.26, a current ratio of 2.75 and a debt-to-equity ratio of 2.93.

Amicus Therapeutics (NASDAQ:FOLD) last issued its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.05). Amicus Therapeutics had a negative net margin of 26.23% and a negative return on equity of 41.47%. The company had revenue of $126.67 million during the quarter, compared to analyst estimates of $121.21 million. During the same quarter last year, the business posted ($0.15) EPS. The company’s revenue for the quarter was up 34.0% on a year-over-year basis. On average, equities analysts expect that Amicus Therapeutics, Inc. will post -0.07 EPS for the current fiscal year.

Insider Activity at Amicus Therapeutics

In related news, CEO Bradley L. Campbell sold 7,500 shares of Amicus Therapeutics stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $11.71, for a total value of $87,825.00. Following the completion of the sale, the chief executive officer now owns 886,654 shares of the company’s stock, valued at approximately $10,382,718.34. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In the last 90 days, insiders sold 22,500 shares of company stock valued at $244,875. Insiders own 2.20% of the company’s stock.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.